Related Experiment Video
Updated: Sep 7, 2025
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Novel Targeting of DNA Methyltransferase Activity Inhibits Ewing Sarcoma Cell Proliferation and Enhances Tumor Cell
Camilla Cristalli1, Maria Cristina Manara1, Sergio Valente2
1Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Abstract:
DNA methylation is an important component of the epigenetic machinery that regulates the malignancy of Ewing sarcoma (EWS), the second most common primary bone tumor in children and adolescents. Coordination of DNA methylation and DNA replication is critical for maintaining epigenetic programming and the DNMT1 enzyme has been demonstrated to have an important role in both maintaining the epigenome and controlling cell cycle. Here, we showed that the novel nonnucleoside DNMT inhibitor (DNMTi) MC3343 induces a specific depletion of DNMT1 and affects EWS tumor proliferation through a mechanism that is independent on DNA methylation. Depletion of DNMT1 causes perturbation of the cell cycle, with an accumulation of cells in the G1 phase, and DNA damage, as revealed by the induction of γH2AX foci. These effects elicited activation of p53-dependent signaling and apoptosis in p53wt cells, while in p53 mutated cells, persistent micronuclei and increased DNA instability was observed. Treatment with MC3343 potentiates the efficacy of DNA damaging agents such as doxorubicin and PARP-inhibitors (PARPi). This effect correlates with increased DNA damage and synergistic tumor cytotoxicity, supporting the use of the DNMTi MC3343 as an adjuvant agent in treating EWS.
Insights
A novel drug, MC3343, targets DNMT1 to disrupt Ewing sarcoma (EWS) cell cycle and DNA replication, independent of DNA methylation. This approach shows promise as an adjuvant therapy for EWS, enhancing treatments like doxorubicin and PARP inhibitors.
Area of Science:
- Epigenetics
- Cancer Biology
- Molecular Oncology
Background:
- Ewing sarcoma (EWS) is a pediatric bone cancer where DNA methylation regulates malignancy.
- DNA methyltransferase 1 (DNMT1) is crucial for maintaining the epigenome and cell cycle control.
Purpose of the Study:
- To investigate the novel nonnucleoside DNMT inhibitor MC3343's effect on EWS.
- To elucidate the mechanism of MC3343 in EWS tumor proliferation.
Main Methods:
- Treatment of EWS cells with MC3343.
- Analysis of DNMT1 depletion, cell cycle progression, DNA damage markers (γH2AX), and p53 signaling.
- Evaluation of MC3343 in combination with DNA damaging agents (doxorubicin, PARP inhibitors).
Main Results:
- MC3343 specifically depletes DNMT1, impacting EWS proliferation independently of DNA methylation.
- DNMT1 depletion causes G1 cell cycle arrest, DNA damage, and p53 activation or DNA instability.
- MC3343 potentiates doxorubicin and PARP inhibitors, leading to synergistic cytotoxicity.
Conclusions:
- MC3343 demonstrates anti-cancer activity in EWS by targeting DNMT1.
- The drug induces cell cycle arrest and DNA damage, activating apoptosis pathways.
- MC3343 shows potential as an adjuvant therapy to enhance conventional treatments for EWS.
Related Concept Videos
02:37DNA Damage can Stall the Cell Cycle
01:38Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...